Fund Holdings — ARCH Venture Management, LLC

Total Portfolio Value
$299.11M
Total Bought
$81.43M
Total Sold
$16.1K
Net Transaction
+$81.41M
Filing Period:
Securities
▲▼
SharesValue ($K)
Q1 2025
▲▼
Q2 2025
▲▼
Change
▲▼
Q1 2025
▲▼
Q2 2025
▲▼
Weight (%)
▲▼
Change
▲▼
VIR BIOTECHNOLOGY INC.(VIR)012,916,663+12,916,663065,10021.76%+65,100
LYELL IMMUNOPHARMA INC.(LYEL)01,820,634+1,820,634016,1135.39%+16,113
VERVE THERAPEUTICS INC.2,008,8092,008,80909,12022,5597.54%+13,439
MAZE THERAPEUTICS INC.(MAZE)4,120,0534,120,053045,36250,59416.91%+5,232
RAPPORT THERAPEUTICS INC.(RAPP)3,728,7383,728,738037,54842,43314.19%+4,885
GOSSAMER BIO INC.(GOSS)8,055,9168,055,91608,7819,9093.31%+1,128
CERO THERAPEUTICS HOLDINGS INC.022,389+22,38902160.07%+216
CERO THERAPEUTICS HOLDINGS, INC.(CERO)22,1020-22,102160—-16
Q32 BIO INC.(FIXX)320,482320,48205324780.16%-54
UNITY BIOTECHNOLOGY INC.1,004,8171,004,81701,0453860.13%-659
ERASCA INC.(ERAS)11,055,55411,055,554015,14614,0964.71%-1,050
BEAM THERAPEUTICS INC.(BEAM)4,540,1324,540,132088,66977,22825.82%-11,441
Page 1 of 1
ARCH Venture Management, LLC — 13F Holdings — Q2 2025 | TickerTrail